MedTrace Logo

Has Inflammation a Significant Implication in Lung Cancer Evolution?

NCT02484872 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2021-08-23

No results posted yet for this study

Summary

Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.

Conditions

  • Lung Neoplasms

Sponsors & Collaborators

  • Jules Bordet Institute

    collaborator OTHER

  • European Lung Cancer Working Party

    lead OTHER

Principal Investigators

  • Anne-Pascale Meert, MD, PhD · Jules Bordet Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2022-12-31
Completion
2023-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02484872 on ClinicalTrials.gov